Beatriz Garcia-Palop1, Emma Movilla Polanco2, Carmen Cañete Ramirez2, Maria Jose Cabañas Poy2. 1. Pharmacy Service, Vall d'Hebron University Hospital, Pº Vall d'Hebron 119-129, 08035, Barcelona, Spain. b.garcia.palop@gmail.com. 2. Pharmacy Service, Vall d'Hebron University Hospital, Pº Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Abstract
BACKGROUND: Neonates may respond differently from adults to drug components. Hence, ingredients that seem safe in adults may not be safe in this age group. OBJECTIVE: To describe the content of harmful excipients in drugs used in our neonatal wards and compare the daily dose a neonate may receive with the accepted daily intake (ADI) in adults. METHODS: All drugs included in the hospital's neonatal treatment guide were reviewed, using information from the package inserts or the summary of product characteristics. Those containing at least one harmful excipient (e.g., metabisulfite, sorbitol) were analyzed. Minimum and maximum usual daily drug doses were determined, and excipient exposure was estimated by extrapolation of the minimum and maximum of excipient referred to the active ingredient. These amounts were compared with ADIs for each excipient in adults. RESULTS: In total, 32 % of intravenous and 62 % of oral formulations used in neonates contained at least one harmful excipient. On quantitative analysis, 25 % of intravenous and 19 % of oral drugs contained harmful excipients exceeding the ADI in adults. CONCLUSION: Several drugs commonly used to treat neonates contain harmful excipients in amounts that may exceed the ADI in adults. Clinicians should be aware of this to prescribe appropriate treatment in this population.
BACKGROUND: Neonates may respond differently from adults to drug components. Hence, ingredients that seem safe in adults may not be safe in this age group. OBJECTIVE: To describe the content of harmful excipients in drugs used in our neonatal wards and compare the daily dose a neonate may receive with the accepted daily intake (ADI) in adults. METHODS: All drugs included in the hospital's neonatal treatment guide were reviewed, using information from the package inserts or the summary of product characteristics. Those containing at least one harmful excipient (e.g., metabisulfite, sorbitol) were analyzed. Minimum and maximum usual daily drug doses were determined, and excipient exposure was estimated by extrapolation of the minimum and maximum of excipient referred to the active ingredient. These amounts were compared with ADIs for each excipient in adults. RESULTS: In total, 32 % of intravenous and 62 % of oral formulations used in neonates contained at least one harmful excipient. On quantitative analysis, 25 % of intravenous and 19 % of oral drugs contained harmful excipients exceeding the ADI in adults. CONCLUSION: Several drugs commonly used to treat neonates contain harmful excipients in amounts that may exceed the ADI in adults. Clinicians should be aware of this to prescribe appropriate treatment in this population.
Authors: Roosmarijn F W De Cock; Catherijne A J Knibbe; Aida Kulo; Jan de Hoon; Rene Verbesselt; Meindert Danhof; Karel Allegaert Journal: Br J Clin Pharmacol Date: 2013-01 Impact factor: 4.335
Authors: A Whittaker; A E Currie; M A Turner; D J Field; H Mulla; H C Pandya Journal: Arch Dis Child Fetal Neonatal Ed Date: 2009-01-21 Impact factor: 5.747
Authors: Domenico Umberto De Rose; Sara Cairoli; Marco Dionisi; Alessandra Santisi; Luca Massenzi; Bianca Maria Goffredo; Carlo Dionisi-Vici; Andrea Dotta; Cinzia Auriti Journal: Int J Mol Sci Date: 2020-08-17 Impact factor: 5.923